Stronger Together; committed to treating
pre-symptomatic and symptomatic SMA in children.

SPINRAZA® has fundamentally changed the disease course of pre-symptomatic and symptomatic SMA compared with natural history.1

We have come a long way from treating the symptoms of SMA to being able to stabilise or improve motor function in children with pre-symptomatic or symptomatic SMA.1 SPINRAZA® helps pre-symptomatic children achieve milestones unexpected in Type I or II SMA and more consistent with normal development.1 The greatest benefit is observed in those with earlier treatment initiation.1

Treatment with SPINRAZA® is also associated with a significant improvement in overall survival in children with Type I SMA compared to untreated patients.1

Camden
4 years*
Pre-symptomatic SMA
Treated with SPINRAZA®
since 2015.

*Age at time of photoshoot

 

The characters shown are real patients and
the required consent to use their pictures/
stories has been obtained from the patients
and families. Photographs are for
illustrative purpose only.

 

Individual results may vary based on several
factors, including severity of disease,
initiation of treatment, and duration of
therapy.

JOIN THE SMA TREATMENT JOURNEY FOR CHILDREN WITH SPINRAZA®?

Dr. Liesbeth de Waele, discusses the new possibilities for treatment of SMA, including in pre-symptomatic and symptomatic children with SMA Type I.

Read about Biogen’s work in early-onset SMA:

References:
1. SPINRAZA® Summary of Product Characteristics. January 2020.